Immunocellular Thera (IMUC) 0.89 $IMUC
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2014.
Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
PR Newswire - Tue Jul 29, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
ImmunoCellular Therapeutics Up 8.6%, Shares Break Through Resistance (IMUC)
Comtex SmarTrend(R) - Wed Jul 23, 11:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 8.6% to $1.01 on 1.2x average daily volume. ImmunoCellular Therapeutics has traded 936,000 shares thus far today, vs. average volume of 802,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.2%) and outperformed the S&P 500 (8.6% to the S&P's 0.2%) during today's trading.
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 9.1% (IMUC)
Comtex SmarTrend(R) - Wed Jul 16, 12:42PM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 9.1% to $0.96 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.0 million shares, vs. average volume of 952,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.4%) and underperformed the S&P 500 (-9.1% to the S&P's 0.4%) during today's trading.
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 5.9% (IMUC)
Comtex SmarTrend(R) - Wed Mar 19, 11:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 5.9% to $1.36 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 1.9 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.0%) and outperformed the S&P 500 (5.9% to the S&P's -0.0%) during today's trading.
ImmunoCellular Therapeutics incurs lower net loss of USD8.8m in 2013
M2 - Fri Mar 14, 4:15AM CDT
Biotechnology company ImmunoCellular Therapeutics (NYSE MKT:IMUC) stated on Thursday its net loss of USD8.8m (USD0.16 per basic and diluted share) for the year ended 31 December 2013.
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:00PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the quarter and year ended December 31, 2013.
ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders
PR Newswire - Tue Mar 11, 3:15PM CDT
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) ("ImmunoCellular" or the "Company" today announced that it will hold its 2014 Annual Meeting of Stockholders on Friday, June 13, 2014. Because the expected meeting date for the 2014 Annual Meeting represents a change of more than thirty days from the anniversary of the Company's 2013 annual meeting of stockholders held on September 20, 2013, the Company has set a new deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act" for inclusion in the Company's proxy materials for the 2014 Annual Meeting. In order to be considered timely, such proposals must comply with the stockholder proposal requirements set forth in the Company's Bylaws and be received by the Company on or before April 15, 2014 at its principal office at 23622 Calabasas Road, Suite 300, Calabasas, California 91302, Attention: Corporate Secretary.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th
PR Newswire - Mon Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.
Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares surge 14% on the day.
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union
PR Newswire - Tue Feb 25, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2014. Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
PR Newswire - Tue Jul 29, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. ImmunoCellular Therapeutics Up 8.6%, Shares Break Through Resistance (IMUC)
Comtex SmarTrend(R) - Wed Jul 23, 11:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 8.6% to $1.01 on 1.2x average daily volume. ImmunoCellular Therapeutics has traded 936,000 shares thus far today, vs. average volume of 802,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.2%) and outperformed the S&P 500 (8.6% to the S&P's 0.2%) during today's trading.
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 9.1% (IMUC)
Comtex SmarTrend(R) - Wed Jul 16, 12:42PM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 9.1% to $0.96 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.0 million shares, vs. average volume of 952,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.4%) and underperformed the S&P 500 (-9.1% to the S&P's 0.4%) during today's trading.
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 5.9% (IMUC)
Comtex SmarTrend(R) - Wed Mar 19, 11:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 5.9% to $1.36 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 1.9 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.0%) and outperformed the S&P 500 (5.9% to the S&P's -0.0%) during today's trading.
ImmunoCellular Therapeutics incurs lower net loss of USD8.8m in 2013
M2 - Fri Mar 14, 4:15AM CDT
Biotechnology company ImmunoCellular Therapeutics (NYSE MKT:IMUC) stated on Thursday its net loss of USD8.8m (USD0.16 per basic and diluted share) for the year ended 31 December 2013.
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:00PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the quarter and year ended December 31, 2013. ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders
PR Newswire - Tue Mar 11, 3:15PM CDT
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) ("ImmunoCellular" or the "Company"
today announced that it will hold its 2014 Annual Meeting of Stockholders on Friday, June 13, 2014. Because the expected meeting date for the 2014 Annual Meeting represents a change of more than thirty days from the anniversary of the Company's 2013 annual meeting of stockholders held on September 20, 2013, the Company has set a new deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act" for inclusion in the Company's proxy materials for the 2014 Annual Meeting. In order to be considered timely, such proposals must comply with the stockholder proposal requirements set forth in the Company's Bylaws and be received by the Company on or before April 15, 2014 at its principal office at 23622 Calabasas Road, Suite 300, Calabasas, California 91302, Attention: Corporate Secretary. 3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th
PR Newswire - Mon Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA. Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares surge 14% on the day.
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union
PR Newswire - Tue Feb 25, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US. 
